In the sensitivity analysis of the outcome of pulmonary embolism, neither the overall immunomodulatory agents nor IL-6 antagonists significantly reduced the risk of pulmonary embolism (Supplementary Figure S4). The gene discussed is IL6; the disease is pulmonary embolism.